Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Vasiliki Mamakou(National and Kapodistrian University of Athens), Eleftheria Zeggini(TUM Klinikum), Bram P. Prins(Wellcome Sanger Institute), Karoline Kuchenbaecker(University of Cambridge), Nikolaοs Tentolouris, Eirini Glezou, George Dedoussis(Harokopio University of Athens), Eleni Zengini(KAT General Hospital of Attica), E Tsompanaki(Athens University of Economics and Business), Anastasia Thanopoulou(National and Kapodistrian University of Athens), Klea Lamnissou(National and Kapodistrian University of Athens), Ioannis Serafetinidis, Lorraine Southam(Essen University Hospital), Athina Karabela, Fragiskos Gonidakis(National and Kapodistrian University of Athens), Eirini Marouli(Queen Mary University of London), Sophie Hackinger(Wellcome Sanger Institute), V.P. Kontaxakis(National and Kapodistrian University of Athens), Nigel W. Rayner(Centre for Human Genetics)
BMC Psychiatry
August 2, 2018
Cited by 5


Related Papers